Eligibility, any sex, with Dementia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Frequency of Agitated and Aggressive Behaviors (Staff Report)Primary· 4-months
The tool used to interview staff about resident behaviors is the Cohen-Mansfield Agitation Inventory (CMAI). Research staff interview nursing staff who know the resident well to ask how frequently 29 agitated/aggressive behaviors occurred in the past week. There are seven response choices for each item, anchored from never (1) to several times per hour (7). Total scores on the CMAI range from 29 to 203, with higher scores representing more frequent agitated/aggressive behaviors. The CMAI is administered at baseline and follow-up.
Group
Value
95% CI
Music & Memory
44.1
± 3.1
Usual Care
47.9
± 3.1
Frequency of Agitated and Aggressive Behaviors (Administrative Data)Secondary· 4 months
The Aggressive Behavior Scale is a 4 item measure describing the frequency of physical behavioral symptoms directed toward others; verbal behavioral symptoms directed toward others; other behavioral symptoms not directed toward others; and behaviors related to resisting necessary care. For each item, frequency in the past week is reported as: behavior not exhibited (0); behavior occurred 1-3 days (1); behavior occurred 4-6 days (2); or behavior occurred daily (3). The Aggressive Behavior Scale ranges from 0 to 12, with higher scores indicating more frequent agitated and/or aggressive behaviors
Group
Value
95% CI
Music & Memory
0.38
± 0.07
Usual Care
0.31
± 0.07
Antipsychotic UseSecondary· 4 months
Any antipsychotic use in the past week, based on Minimum Data Set (standardized assessment of nursing home residents). Comparison of percent with any use will be compared for treatment and control populations. Measure type of mean is chosen based on adjusted percentage with standard errors from a multilevel, difference in difference regression models.
Group
Value
95% CI
Music & Memory
43.6
± 2.3
Usual Care
39.7
± 2.2
Antianxietal UseSecondary· 4 months
Any antianxietal use in the past week , based on Minimum Data Set (standardized assessment of nursing home residents). Comparison of adjusted percent with any use will be compared for treatment and control populations. Measure type of mean is chosen based on adjusted percentage with standard errors from a multilevel, difference in difference regression models.
Group
Value
95% CI
Music & Memory
32.3
± 2.5
Usual Care
33.7
± 2.6
Antidepressant UseSecondary· 4 months
Any antidepressant use in the past week, based on Minimum Data Set (standardized assessment of nursing home residents). Comparison of percent with any use will be compared for treatment and control populations. Measure type of mean is chosen based on adjusted percentage with standard errors from a multilevel, difference in difference regression models.
Group
Value
95% CI
Music & Memory
63.8
± 1.8
Usual Care
68.6
± 1.8
Hypnotic UseSecondary· 4 months
Any hypnotic use in the past week, based on Minimum Data Set (standardized assessment of nursing home residents). Comparison of percent with any use will be compared for treatment and control populations.
Group
Value
95% CI
Music & Memory
1.62
Usual Care
0.95
DepressionSecondary· 4 months
The Patient Health Questionnaire is a 9-item screening assessment for depression severity. For each item, respondents indicate the frequency of the symptom in the past 2 weeks using the following choices: never or one day (0); 2-6 days (1); 7-11 days (2); or 12-14 days (3). Total scores range from 0 to 27, with higher scores indicating more frequent depressive symptoms. Average total scores will be compared for treatment and control populations.
Group
Value
95% CI
Music & Memory
2.33
± 0.44
Usual Care
1.61
± 0.47
Sponsor's own description
The purpose of this trial is to test the effects of a personalized music intervention (Music and Memory, Inc.) on agitated and aggressive behaviors for nursing home residents with dementia.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia
· NA
· recruiting
NCT07290387 — Tele-Savvy for Latino Caregivers
· NA
· recruiting
NCT06088810 — The Impact of Music Intervention on Sleep
· NA
· recruiting
NCT07482800 — Dementia in Fiction and Clinical Narratives
· recruiting
NCT07392944 — Multicomponent Exercise Program on Physical Function, Cognition and Falls Risk Among Older Adults Living in Nursing Home
· NA
· recruiting
Other Brown University trials
Trials by the same sponsor.
NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g
· Phase 2
· not yet recruiting
NCT07118618 — Probenecid Administration for Alcohol Craving and Consumption
· Phase 2
· recruiting
NCT07398443 — Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults
· NA
· recruiting
NCT05901766 — Effect of Iodine-containing Multiple Micronutrient During Lactation on Infant Neurodevelopment
· Phase 4
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brown University
Last refreshed: 28 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04850807.